Feds Decline to Join Allergan Glaucoma Suit

The federal government decided not to join a false claims act suit against Allergan over its glaucoma drug Lumigan (bimatoprost).

The 2014 whistleblower suit, which was unsealed, accused the company of hiding the health risks of the medication and collecting reimbursement from public insurance programs that amounted to hundreds of millions of dollars in yearly sales.

Twenty-nine states and Washington, D.C. joined the federal government in declining to intervene. The government reserved its right to intervene later for “good cause.”